Cyclerion Total Assets from 2010 to 2024

CYCN Stock  USD 2.75  0.18  6.14%   
Cyclerion Therapeutics Total Assets yearly trend continues to be very stable with very little volatility. Total Assets are likely to drop to about 12.7 M. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals
 
Total Assets  
First Reported
2016-12-31
Previous Quarter
11.4 M
Current Value
10.1 M
Quarterly Volatility
69 M
 
Covid
Check Cyclerion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclerion Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 355 K or Selling General Administrative of 16.2 M, as well as many indicators such as Price To Sales Ratio of 90.71, Dividend Yield of 0.0 or PTB Ratio of 0.73. Cyclerion financial statements analysis is a perfect complement when working with Cyclerion Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclerion Therapeutics Correlation against competitors.
To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.

Latest Cyclerion Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Cyclerion Therapeutics over the last few years. Total assets refers to the total amount of Cyclerion Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cyclerion Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Cyclerion Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclerion Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 13.37 M10 Years Trend
Slightly volatile
   Total Assets   
       Timeline  

Cyclerion Total Assets Regression Statistics

Arithmetic Mean29,689,420
Geometric Mean10,501,278
Coefficient Of Variation178.32
Mean Deviation36,282,499
Median5,470,000
Standard Deviation52,942,903
Sample Variance2803T
Range182.6M
R-Value0.34
Mean Square Error2677.1T
R-Squared0.11
Significance0.22
Slope3,981,754
Total Sum of Squares39241.3T

Cyclerion Total Assets History

202412.7 M
202313.4 M
202218.1 M
202159.3 M
2020115.4 M
2019186.5 M
20187.4 M

Other Fundumenentals of Cyclerion Therapeutics

Cyclerion Therapeutics Total Assets component correlations

About Cyclerion Therapeutics Financial Statements

Cyclerion Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Cyclerion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Assets13.4 M12.7 M

Pair Trading with Cyclerion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Cyclerion Stock

  0.52MBIO Mustang BioPairCorr
  0.45RANI Rani TherapeuticsPairCorr
  0.41REVBW Revelation BiosciencesPairCorr
  0.36DYAI Dyadic InternationalPairCorr
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Information and Resources on Investing in Cyclerion Stock

When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:
Check out the analysis of Cyclerion Therapeutics Correlation against competitors.
To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.29)
Revenue Per Share
0.586
Quarterly Revenue Growth
0.141
Return On Assets
(0.47)
Return On Equity
(1.50)
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.